missing translation for 'onlineSavingsMsg'
Learn More

Emerin (Papillary Thyroid Carcinoma and EDMD Marker) Mouse, Clone: EMD/2167, enQuireBio™

Mouse Monoclonal Antibody

2035.00 SEK - 5965.00 SEK

Specifications

Antigen Emerin (Papillary Thyroid Carcinoma and EDMD Marker)
Clone EMD/2167
Concentration 200μg/mL
Applications Immunohistochemistry
Classification Monoclonal
View More Specs

Products 2
Product Code Brand Quantity Price Quantity & Availability  
Product Code Brand Quantity Price Quantity & Availability  
15989937
View Documents
EnquireBio
2010-MSM1-P0
20 μg This item is currently unavailable or has been discontinued.
View the product page for possible alternatives.
N/A
15999937
View Documents
EnquireBio
2010-MSM1-P1
100 μg
5965.00 SEK
100µg
Please to purchase this item. Need a web account? Register with us today!
Description

Description

Specifications

Specifications

Emerin (Papillary Thyroid Carcinoma and EDMD Marker)
200μg/mL
Monoclonal
Mouse
10mM PBS with 0.05% BSA and 0.05% azide. Also available without BSA and Azide.
Recombinant human Emerin protein fragment (apprx. aa 56-167)
Primary
Short term: Store at 2-4°C. Long term, aliquot and store at -20°C.
37kDa
EMD/2167
Immunohistochemistry
Unconjugated
RUO
2010
IgG1
Protein A/G purified from Bioreactor concentrate.
Nuclear Membrane
K-562, HeLa or Jurkat cells. Kidney or Skin
Videos
SDS
Documents

Documents

Product Certifications
Product Content Correction

Your input is important to us. Please complete this form to provide feedback related to the content on this product.

Product Title
Emerin (Papillary Thyroid Carcinoma and EDMD Marker) Mouse, Clone: EMD/2167, enQuireBio™

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Thank You! Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.